SFL’s CEO Shayesteh Fürst-Ladani> will participate in the upcoming virtual2020 BIO Digital International Convention> (8-12 June). The BIO Digital partnering meeting brings together biotechnology and pharma companies that are active in drug development, clinical trials and supply, cell and gene therapy, and drug discovery; areas that compliment various aspects of SFL’s expertise areas, including advanced therapies and biotechnology, development and drug discovery, precision medicines, vaccines, digital health, regulations, innovation and patient access.

SFL provides strategic and operational support for projects covering all life-cycle stages from early development and registration of new products to regulatory maintenance and market access activities of approved healthcare products, utilizing its unique combination of expertise and a multi-disciplinary approach. In addition, SFL can also act as the Marketing Authorization Holder (MAH) for pharma companies, who do not have a registered subsidiary in the EU or Switzerland.Contact us> to arrange a 1-1 meeting with Shayesteh or Delphine during the BIO Digital International Convention.